PolyPeptide Group AG shareholders approved all proposals put forward by the Board of Directors at the company's fifth annual General Meeting with a large majority. The specialized global Contract Development & Manufacturing Organization for peptide-based active pharmaceutical ingredients saw 80.85% of issued registered shares represented at the meeting held in Zug, Switzerland.
All six members of the Board of Directors proposed for re-election were appointed for terms ending at the conclusion of the next annual General Meeting in 2027. Peter Wilden was re-elected as Chair of the Board of Directors, while Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for the same period.
Shareholders approved several additional proposals including the re-election of Statutory Auditors and Independent Proxy, approval of maximum aggregate compensation amounts for the Board of Directors and Executive Committee, and granted discharge to all members of both bodies for their activities during the 2025 financial year. The Management Report, Statutory Financial Statements, Consolidated Financial Statements, report on non-financial matters for 2025, and the Remuneration Report 2025 were all approved through voting.
The meeting results demonstrate strong shareholder support for PolyPeptide's current leadership and strategic direction at a time when peptide therapeutics represent one of the fastest-growing segments in pharmaceutical development. As a specialized CDMO serving pharmaceutical and biotech companies, PolyPeptide's stability in governance provides assurance to partners developing critical peptide-based treatments for conditions including metabolic diseases like those targeted by GLP-1 therapies.
For investors, the overwhelming approval of all proposals indicates confidence in management's handling of the company's operations and financial reporting. The approval of compensation structures and financial reports suggests alignment between shareholder interests and executive leadership decisions. This governance stability is particularly important for a company operating in the highly regulated pharmaceutical manufacturing sector where long-term partnerships and consistent quality standards are essential.
The minutes of the AGM 2026 will be available within 15 days on the company's website at https://polypeptide.com. The next annual General Meeting is scheduled for April 7, 2027. PolyPeptide's shares continue to trade on SIX Swiss Exchange under the symbol PPGN, with the company maintaining six GMP-certified facilities across Europe, the United States, and India serving global pharmaceutical development needs.
